当前位置: 首页 >> 检索结果
1. Phase 2b Trial of a NaV1.8 Inhibitor for Acute Pain.
作者: Neil Singla.;Nathaniel P Katz.;Ben Vaughn.;Timothy Rogier.;Todd Bertoch.;Harold Minkowitz.;Mallory Loflin.
来源: N Engl J Med. 2026年395卷5期454-464页
Nav1.8, a voltage-gated sodium channel expressed in the peripheral nervous system, has a critical role in pain signaling. Previous trials of NaV1.8 inhibitors have shown effectiveness in reducing postoperative pain.
2. Enfortumab Vedotin and Pembrolizumab in Cisplatin-Eligible Bladder Cancer.
作者: Matthew D Galsky.;Begoña P Valderrama.;Marco Maruzzo.;Albert Font.;Tudor Ciuleanu.;Jonathan Chatzkel.;Takuya Koie.;Christopher J Hoimes.;Javier Puente.;Yousef Zakharia.;Eli Rosenbaum.;Katharina Boehm.;Yohann Loriot.;Jens Bedke.;Thomas B Powles.;Andrea Necchi.;Pawel Wiechno.;Carlos Álvarez-Fernández.;Tae-Hwan Kim.;Niara Oliveira.;Thomas W Flaig.;Heidi S Wirtz.;Michael Mihm.;Qinlei Huang.;Aljosja Rogiers.;Blanca Homet Moreno.;Alfonso Gómez de Liaño.; .
来源: N Engl J Med. 2026年395卷4期338-348页
Neoadjuvant cisplatin-based chemotherapy is a standard therapy for muscle-invasive bladder cancer. The efficacy and safety of neoadjuvant and adjuvant (perioperative) enfortumab vedotin-pembrolizumab as compared with neoadjuvant cisplatin-based chemotherapy in persons with this cancer are unclear.
3. Extended Dual Antiplatelet Therapy for Multivessel Coronary Artery Disease.
作者: Jinwei Tian.;Zhuozhong Wang.;Yan Wang.;Fan Wang.;Xiang Peng.;Jiandong Xiao.;Chunjie Li.;Xinyu Hou.;Qian Tong.;Xi Yu.;Guangren Gao.;Peng Zhao.;Jie Zhao.;Ying Liu.;Zhexue Qin.;Haijing Lu.;Shujiang Zhang.;Shengli Li.;Zhiyuan Weng.;Huifang Tang.;Yuquan He.;Chunpeng Zhang.;Yong Liu.;Jun Jiang.;Jinying Zhang.;Lei Cai.;Lili Xiu.;Gary S Mintz.;Duolao Wang.;Gregg W Stone.;Bo Yu.; .
来源: N Engl J Med. 2026年395卷3期233-242页
Patients with multivessel coronary artery disease often receive 12 months of dual antiplatelet therapy (DAPT) after stenting to reduce the risk of ischemic events. Whether extending DAPT beyond 12 months in event-free patients with multivessel disease provides a benefit is uncertain.
4. Continuous or Fixed-Duration Maintenance Therapy in Multiple Myeloma.
作者: Shaji Kumar.;Susanna Jacobus.;Adam Cohen.;Matthias Weiss.;Natalie Callander.;Avina Singh.;Terri Parker.;Michael Green.;Raymond Thertulien.;Benjamin Parsons.;Pankaj Kumar.;Prashant Kapoor.;Aaron Rosenberg.;Elie Dib.;Daniel Almquist.;Jeffrey Zonder.;Edward Faber.;Zihan Wei.;Kenneth Anderson.;Sagar Lonial.;Paul Richardson.;Robert Orlowski.;Lynne Wagner.;S Vincent Rajkumar.
来源: N Engl J Med. 2026年395卷3期221-232页
Current treatment of newly diagnosed multiple myeloma involves lenalidomide maintenance therapy given until disease progression. The appropriate duration of maintenance therapy with lenalidomide has been unclear.
5. Meningococcal B Vaccine to Prevent Neisseria gonorrhoeae Infection.
作者: Kate L Seib.;Basil Donovan.;Fengyi Jin.;Caroline Thng.;Barbara Yeung.;Nicholas Comninos.;Rohan I Bopage.;Anik Ray.;Alison Mahony.;Eric P F Chow.;Marcus Y Chen.;Kate Maddaford.;Helen Lau.;Portia Westall.;Dan Lu.;Benjamin R Bavinton.;Kathy Petoumenos.;David M Whiley.;Michael P Jennings.;Amy V Jennison.;John Kaldor.;Rebecca Guy.;Monica M Lahra.;Jane Costello.;Brent Mackie.;David J Templeton.;Beng Eu.;Mark O'Reilly.;Christopher K Fairley.;Anna McNulty.;Rick Varma.;David A Lewis.;Andrew E Grulich.; .
来源: N Engl J Med. 2026年395卷4期349-361页
No vaccines are currently licensed for the prevention of Neisseria gonorrhoeae infection. Observational studies suggest that the four-component meningococcal serogroup B vaccine (4CMenB) may reduce the risk of gonorrhea.
6. Ensartinib in Resected ALK-Positive Non-Small-Cell Lung Cancer.
作者: Dongsheng Yue.;Meijuan Huang.;Pingping Song.;Yuejun Chen.;Bin Li.;Junke Fu.;Jianji Guo.;Chao Cheng.;Qixun Chen.;Shidong Xu.;Hongxu Liu.;Fang Lv.;Jian Hu.;Ke Jiang.;Weimin Mao.;Bo Shen.;Feng Ye.;Jie Li.;Xueying Zhang.;Shiping Guo.;Bentong Yu.;Yuming Zhu.;Ming Wu.;Wei Zheng.;Fang Chen.;Zhengfu He.;Yuansong Bai.;Hua Xin.;Keneng Chen.;Naiquan Mao.;Yu Zhang.;Bo Wang.;Lei Zhang.;Xingwu Chen.;Xinyu Mei.;Liyun Miao.;Runjie Wang.;Gaofeng Li.;Juntao Yao.;Jun Zhao.;Chun Chen.;Junfeng Liu.;Li Wei.;Xiaolong Yan.;Bo Jin.;Xianling Liu.;Zhidong Liu.;Hui Tian.;Wenqun Xing.;Lin Yang.;Di Ge.;Xiangnan Li.;Shanqing Li.;Yongxiang Song.;Aimin Zang.;Dahai Zhang.;Wu Zhuang.;Zijin Liu.;Xiaobin Yuan.;Tao Fu.;Zhilin Shen.;Xiaojun Zhang.;Qiuyue Cao.;Luyang Zhao.;Li Mao.;Lieming Ding.;You Lu.;Changli Wang.; .
来源: N Engl J Med. 2026年395卷2期151-161页
Anaplastic lymphoma kinase (ALK) inhibitors have emerged as promising agents for patients with resectable ALK-positive non-small-cell lung cancer (NSCLC). Whether ensartinib, a second-generation ALK inhibitor, is safe and effective in such patients is unknown.
7. Setmelanotide for the Treatment of Acquired Hypothalamic Obesity.
作者: Jennifer L Miller.;Hanneke M van Santen.;Susan A Phillips.;Jill Hamilton.;Jens Aberle.;Thozhukat Sathyapalan.;Zainaba Mohamed.;Shana E McCormack.;Ashley H Shoemaker.;Megan M Kelsey.;Luma Ghalib.;Guenter Stalla.;Vidhu V Thaker.;Reema Habiby.;Katie Larson Ode.;Martin Wabitsch.;Mehul Dattani.;M Jennifer Abuzzahab.;Hussein Abdullatif.;Ryan Morgan.;Margaret Stefater-Richards.;Vanita R Aroda.;Carsten Friedrich.;Joan C Han.;Hiraku Ono.;Keisuke Nagasaki.;Tomohiro Tanaka.;Tsuyoshi Isojima.;Hiroshi Arima.;Cecilia Scimia.;Guojun Yuan.;Hermann L Müller.;Christian L Roth.; .
来源: N Engl J Med. 2026年395卷2期138-150页
A phase 2 trial of setmelanotide, a melanocortin-4 receptor agonist, showed substantial weight loss in patients with acquired hypothalamic obesity, but additional data are needed.
8. Rituximab versus Ocrelizumab in Newly Diagnosed Relapsing Multiple Sclerosis.
作者: Øivind Torkildsen.;Hilde Kjelgaard Brustad.;Einar August Høgestøl.;Karl Bjørnar Alstadhaug.;Alok Bhan.;Heidi Øyen Flemmen.;Andrea Habbestad.;Rune A A Høglund.;Marissa LeBlanc.;Peter Lopen.;Åslaug Rudjord Lorentzen.;Åse Hagen Morsund.;Andreas Lossius.;Rigmor Lundby.;Gro O Nygaard.;Brit Ellen Rød.;Cecilia Smith Simonsen.;Linn Steffensen.;Hilde Torgauten.;Fredrik Piehl.;Stig Wergeland.;Kjell-Morten Myhr.; .
来源: N Engl J Med. 2026年395卷1期44-53页
Anti-CD20 monoclonal antibodies are effective for relapsing multiple sclerosis. However, data from head-to-head trials are lacking.
9. Adjuvant Pembrolizumab plus Belzutifan for Renal-Cell Carcinoma.
作者: Toni K Choueiri.;Robert J Motzer.;Jose A Karam.;Wesley Yip.;Cristina Suárez.;Dingwei Ye.;Zhisong He.;Christian Caglevic.;Tom Ferguson.;Yen-Hwa Chang.;Carlos Rojas.;Roberto Iacovelli.;Yüksel Ürün.;Elena Verzoni.;Juan Carlos Vázquez Limón.;Camillo Porta.;Robert G Uzzo.;Jae Lyun Lee.;Balaji Venugopal.;Rana R McKay.;Hans Hammers.;Hideaki Miyake.;Jad Chahoud.;Hong Liu.;Joseph E Burgents.;Manish Sharma.;Thomas B Powles.; .
来源: N Engl J Med. 2026年395卷1期32-43页
Adjuvant pembrolizumab improves disease-free and overall survival among patients with resected clear-cell renal-cell carcinoma. The hypoxia-inducible factor 2α inhibitor belzutifan has activity in advanced disease. Adjuvant pembrolizumab with belzutifan may further improve outcomes in patients with clear-cell renal-cell carcinoma at increased risk for recurrence.
10. Ten-Year Outcomes after CAR T-Cell Therapy for B-Cell Lymphomas.
作者: Marco Ruella.;Luca Paruzzo.;Emeline R Chong.;Elise A Chong.;Daniel J Landsburg.;Sunita D Nasta.;Pooja Devi.;Peter Michener.;Federico Stella.;Alberto Carturan.;Ellen B Napier.;Vivianna M Van Deerlin.;Patrizia Porazzi.;Bruce L Levine.;Noelle Frey.;David L Porter.;Joseph A Fraietta.;Jakub Svoboda.;Carl H June.;Stephen J Schuster.
来源: N Engl J Med. 2026年394卷24期2440-2448页
Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is a standard treatment for relapsed or refractory B-cell non-Hodgkin lymphomas. Long-term results and curative potential remain uncertain.
11. A Pragmatic Trial of a 6-Month Strategy for Rifampicin-Resistant Tuberculosis.
作者: Francesca Conradie.;Tasnim Badat.;Asanda Poswa.;Shakira Rajaram.;Shaneen Kooverjee.;Gary Maartens.;Graeme Meintjes.;Jennifer Hughes.;H Simon Schaaf.;Pauline Howell.;Norbert Ndjeka.;Patrick P J Phillips.
来源: N Engl J Med. 2026年394卷24期2429-2439页
Safer, more effective treatment regimens for rifampicin-resistant tuberculosis are needed.
12. Cefazolin for Methicillin-Susceptible Staphylococcus aureus Bacteremia.
作者: .;Todd C Lee.;Lauren A Barina.;Genevieve Walls.;Anna L Goodman.;Dafna Yahav.;Matthew P Cheng.;Marc Bonten.;Asha C Bowen.;Tom Boyles.;Nick Daneman.;Miquel B Ekkelenkamp.;Nesrin Ghanem-Zoubi.;Marjolein P M Hensgens.;Nynke G L Jager.;Achim J Kaasch.;Ilse J E Kouijzer.;Roger J Lewis.;Thomas Lumley.;David C Lye.;Emily G McDonald.;Genevieve McKew.;Alistair R D McLean.;Brendan J McMullan.;Zoe K McQuilten.;Susan C Morpeth.;David L Paterson.;Jason A Roberts.;J Owen Robinson.;Hiroki Saito.;Matthew Scarborough.;Jaap Ten Oever.;Rebecca M Turner.;Jonas Tverring.;Sebastiaan J van Hal.;Steve A Webb.;Lynda M Whiteway.;Cesar A Arias.;Andrew Henderson.;George S Heriot.;Tom L Snelling.;Kevin Afra.;Shabinah S Ali.;Sharon Amit.;Nicholas A Anagnostou.;Sophia Archuleta.;Stephen J Aston.;Eugene Athan.;Nadav Baharav.;Anthony D Bai.;Bridget E Barber.;Abinayah Baskaran.;Michelle M A Berkeley.;Emma J Best.;Nilesh R Bhilave.;Max G Bloomfield.;Katherine A Bond.;Jennifer Bostock.;Carly L Botheras.;Mark A Boyd.;Sophia M E Bradshaw.;Elizabeth J Briggs.;Philip N Britton.;Anita J Campbell.;Beau Z Carr.;James A Chancellor.;Kevin Chen.;Elaine Y Cheong.;Ka Lip Chew.;Po Ying Chia.;Rispah Chomba.;Brian S W Chong.;Chris J N Clews.;Jonathan M Cohen.;Robert J Commons.;Tim Cutfield.;Peter Daley.;Diane S Daniel.;Jane Davies.;Partha De.;Justin T Denholm.;Mia Di Virgilio.;Yael Dishon-Benattar.;Ravindra Dotel.;Erick H Duan.;Nicholas Easom.;Noa Eliakim-Raz.;Michelle M England.;Mark Fahmy.;Aidan R Findlater.;Katie L Flanagan.;Ethan Z J Foo.;Hong Foo.;Daniel P Forster.;Michael Fralick.;Jaimie L Frazer.;Andrew P Gador-Whyte.;Katherine Garnham.;Greg J German.;Niladri Ghosh.;Elisabeth H Gisolf.;Stefano G Giulieri.;Susan R Goulding.;Jennifer M Grant.;Daniel Gregson.;Kate C Grimwade.;Mordechai Grupper.;Stephen D Guy.;Amanda Gwee.;Victoria G Hall.;Erica J Hardy.;David J Harris.;James Hatcher.;Mark R Hobbs.;Natasha E Holmes.;Benjamin P Howden.;Paul J Huggan.;Zoe A Jennings.;Jennie Johnstone.;Thomas Juniper.;Shirin Kalimuddin.;Musaiwale Kamfose.;Christopher Kandel.;Matthew J Kelly.;Robert A Kozak.;Michelle Kümin.;Francois Lamontagne.;Jillian S Y Lau.;Ivor Russel Lee.;Ray J Lin.;Daisy Lindsay.;Martin J Llewelyn.;Yves Longtin.;Sylvain A Lother.;Christopher E Luey.;Derek R MacFadden.;Andrew A Mahony.;Catherine Malden.;Isabelle Malhamé.;Laurens A Manning.;Michael Marks.;Leslie J Martin.;Gail V Matthews.;Patrick H McGann.;James H McMahon.;Alexandra Melon.;Vidthiya Menon.;Dominik Mertz.;Michael P Meyer.;James S Molton.;Jocelyn M Mora.;Ed Moran.;Leanne M Mortimer.;Satwik Motaganahalli.;Matthew P Muller.;Alasdair P S Munro.;Fionnuala A Murray.;Srinivas Murthy.;Vanathi Nagendra.;Henco Nel.;David W J New.;Vi Nguyen.;Grace Norton.;Katherine M Norton.;Clare B Nourse.;Clemency J S Nye.;Kevin O'Callaghan.;Matthew V N O'Sullivan.;Sean W X Ong.;Akaninyene A Otu.;Melissa Owen.;Jesse Papenburg.;Leighanne O Parkes.;Mical Paul.;Santiago Perez-Patrigeon.;Neta Petersiel.;Lina Petrella.;Sarah L Pett.;David Pham.;Chiara J Piazzese.;Sebastien Poulin.;Renata Rehak.;Elissa Rennert-May.;Alexander J Richards.;Benjamin A Rogers.;Euna Sahng.;Brenda Salada.;Oded Scheuerman.;Kellie Schneider.;Thomas R Schulz.;Kevin L Schwartz.;Peter A Simos.;Harsimran Singh.;Fleur S Sinkeler.;Simon Smith.;Benjamin J Smith.;Stephanie W Smith.;Ranjani Somayaji.;Christine Sommerville.;Rima X J Song.;David C Sowden.;Michael J Stark.;Neil R H Stone.;Tobias Strunk.;Archana Sud.;Khine P Swe.;Caitlin R Symons.;Yen Ee Tan.;Thijs Ten Doesschate.;Siew Yee Thien.;Ashmitha Thomas.;Mohamad-Ali Trad.;Adrian R Tramontana.;Jennifer L Y Tsang.;Kimberly Ulett.;Jonathan Underwood.;Berend J van Welzen.;Gloria Vazquez-Grande.;Diana C Velasquez Reyes.;Janneke D M Verberk.;Lesley M Voss.;Denise Ward.;Rachel H Webb.;Timothy J Whitmore.;Anat Wieder-Finesod.;Heather L Wilson.;Evan W Wilson.;Hei Man Wong.;Kate Wong She.;Terence Wuerz.;Deborah L Yamamura.;Alastair Yeoh.;Boris Long Hei Yow.;Michael Dymock.;Robert K Mahar.;Anna McGlothlin.;Julie A Marsh.;Joshua S Davis.;Steven Y C Tong.
来源: N Engl J Med. 2026年394卷23期2329-2339页
Staphylococcus aureus bacteremia is associated with high mortality. Whether cefazolin or an antistaphylococcal penicillin should be preferred for the treatment of methicillin-susceptible S. aureus bacteremia is unclear.
13. Talquetamab-Daratumumab in Relapsed or Refractory Myeloma.
作者: Roberto Mina.;Meral Beksac.;Paula Rodríguez-Otero.;Wenming Chen.;María-Victoria Mateos.;Jian Li.;Philippe Moreau.;Yael C Cohen.;Chang-Ki Min.;Tomas Jelinek.;Jing Christine Ye.;Hila Magen.;Samuel M Rubinstein.;Weijun Fu.;Vania Hungria.;Guldane Cengiz Seval.;Joao Samuel Farias.;Jakub Radocha.;Senem Maral.;Mehmet Turgut.;Youngil Koh.;Daniel O'Leary.;Jayr Schmidt Filho.;Raymond Thertulien.;Gang An.;Shang-Yi Huang.;Sebastian Grosicki.;Agata Tyczyńska.;Rahul Banerjee.;Matthew J Pianko.;Joaquín Martínez-López.;Pawel Steckiewicz.;Dai Maruyama.;Kentaro Fukushima.;Albert Oriol.;Jordi Lopez Pardo.;Hartmut Goldschmidt.;Charlotte Pawlyn.;Aurore Perrot.;Elena Zamagni.;Meletios A Dimopoulos.;Leo Rasche.;Jaszianne Tolbert.;William Terry.;Christelle Courtoux.;Xiao Liu.;Sandra Y Vasey.;Kaitlyn Connors.;Mariacristina Festa.;Christoph Heuck.;Angélique Langlois.;Lisa O'Rourke.;Jiangxiu Zhou.;Xiang Qin.;Jiashen Lu.;Joy Gong.;Diego Vieyra.;Peter M Voorhees.; .
来源: N Engl J Med. 2026年395卷7期671-683页
Talquetamab, a bispecific antibody targeting GPRC5D and CD3, has led to durable responses in patients with heavily pretreated relapsed or refractory multiple myeloma in phase 1-2 trials, with a limited effect on normal B cells.
14. Subretinal Gene Therapy for X-Linked Retinoschisis.
作者: Licong Liang.;Kaiqin She.;Chengda Ren.;Rui Li.;Meng Liao.;Zhiyan Tao.;Fanfei Liu.;Jing Su.;Ming Hu.;Yiliu Yang.;Xiaoyue Wang.;Charlotte L Zhang.;Li Bao.;Qin Chen.;Kang Zhang.;Yuquan Wei.;Yang Yang.;Fang Lu.
来源: N Engl J Med. 2026年394卷22期2223-2234页
X-linked retinoschisis is a recessive disease characterized by progressive macular degeneration and vision loss due to pathogenic variation in RS1.
15. Conservative Oxygen for Unresponsive Patients after Cardiac Arrest.
作者: .;Carol L Hodgson.;Diane Mackle.;Anne M Mather.;Michael Bailey.;Richard Beasley.;Niña Beehre.;Stephen Bernard.;Kathy Brickell.;Bianca Crichton.;Adam M Deane.;Glenn Eastwood.;Simon Finfer.;Seton Henderson.;Alisa M Higgins.;Anna Hunt.;Jessica Kasza.;Cassie Lawrence.;Natalie J Linke.;Edward Litton.;Christine F McDonald.;James Moore.;Alistair D Nichol.;Shaanti Olatunji.;Rachael Parke.;Sandra Peake.;Paul Secombe.;Ian M Seppelt.;Ary Serpa Neto.;Tony Trapani.;Anne Turner.;Andrew Udy.;Paul J Young.
来源: N Engl J Med. 2026年395卷6期571-581页
In patients who are unresponsive after resuscitation from cardiac arrest, limiting oxygen exposure to that necessary to achieve acceptable oxygenation may increase the likelihood of survival with a favorable functional outcome.
16. Hospital Policy of Tranexamic Acid to Reduce Transfusion in Major Noncardiac Surgery.
作者: Brett L Houston.;Daniel I McIsaac.;Rodney H Breau.;Salmaan Kanji.;Peter Greenstreet.;Meghan Andrews.;Sinziana Avramescu.;Hema S Bagry.;Robert Balshaw.;Jayesh Daya.;Kaitlin Duncan.;Christopher C Harle.;Eric Jacobsohn.;Tina Kerelska.;Marshall Pitz.;Paul Komenda.;Sarah McIsaac.;Tim Ramsay.;Tarit Saha.;Alan Tinmouth.;Angela Recio.;Daniel Szoke.;Marshall Tenenbein.;Sarah Slagerman.;Dayna Solvason.;Robert Talarico.;Dean A Fergusson.;Ryan Zarychanski.
来源: N Engl J Med. 2026年394卷24期2419-2428页
Whether a hospital policy of tranexamic acid administration for patients undergoing major noncardiac surgery safely reduces the need for red-cell transfusion is uncertain.
17. Finerenone in Persons with Chronic Kidney Disease without Diabetes.
作者: Hiddo J L Heerspink.;Brendon L Neuen.;Rajiv Agarwal.;David Z I Cherney.;Carolyn S P Lam.;Katherine R Tuttle.;Christoph Wanner.;Pantelis Sarafidis.;Niels Jongs.;J David Smeijer.;Meike Brinker.;Nicole Rethemeier.;Patrick Schloemer.;Paula Vesterinen.;David Goldsbury.;Sara Dizayee.;Jon W Mares.;Vlado Perkovic.; .
来源: N Engl J Med. 2026年395卷6期533-545页
In randomized trials, finerenone, a nonsteroidal mineralocorticoid receptor antagonist, improved kidney and cardiovascular outcomes in patients with type 2 diabetes and chronic kidney disease (CKD). Whether finerenone has similar effects in patients without diabetes who have CKD is unknown.
18. Kidney Transplantation in Two Highly Sensitized Candidates after CAR T-Cell Therapy.
作者: Vijay G Bhoj.;Mary Kaminski.;Huiwu Zhao.;Kyle Jackson.;Wei Wang.;Chengyang Liu.;Robert A Montgomery.;Nicole Ali.;Massimo Mangiola.;Thomas R Spitzer.;Kassem Safa.;Vikram Pattanayak.;Raeda Taj.;Joy Chiu.;Thanh-Mai Bui.;Elizabeth M Sonnenberg.;James F Markmann.;Michael C Milone.;Carl H June.;Don L Siegel.;Joseph A Fraietta.;Vanessa Gonzalez.;Michela Locci.;Matthew Palmer.;Dimitri Monos.;Wei-Ting Hwang.;Tina Sledge.;Nancy D Bridges.;Julia S Goldstein.;Jonah Odim.;Stuart C Sweet.;Behdad D Besharatian.;Sabiha M Hussain.;Nicholas K Brown.;Malek Kamoun.;Alfred L Garfall.;Ali Naji.
来源: N Engl J Med. 2026年394卷21期2117-2125页
HLA sensitization poses a major challenge to kidney transplantation for patients with end-stage kidney disease, especially for highly sensitized candidates. Attempts at antibody elimination (desensitization) have had inconsistent efficacy and have often failed to produce sustained reductions in anti-HLA antibodies in patients with the highest level of sensitization (calculated panel-reactive antibody score, ≥99.9%). We now report the results for the safety run-in cohort of a multicenter phase 1 clinical study evaluating the safety and efficacy of combined CD19-targeted and B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor (CAR) T cells in eliminating the cellular sources of preformed anti-HLA antibodies (ClinicalTrials.gov number, NCT06056102). Kidney transplantation was performed in two highly sensitized candidates after desensitization with the use of dual CAR T-cell therapy.
19. All-Oral Treatment of Newly Diagnosed Acute Myeloid Leukemia.
作者: Gail J Roboz.;Amer M Zeidan.;Gabriel N Mannis.;Pau Montesinos.;Montserrat Arnan.;Michael R Savona.;Olatoyosi Odenike.;James K McCloskey.;Harshad V Amin.;Amir T Fathi.;Teresa Bernal Del Castillo.;Gabriela Rodríguez-Macías.;Jane L Liesveld.;Annie P Im.;Jan Cerny.;Teresa C Gentile.;Aram Oganesian.;Danna Chan.;Yubing Wan.;Margit Dijkstra.;Harold N Keer.;Elizabeth A Griffiths.;Courtney D DiNardo.
来源: N Engl J Med. 2026年394卷21期2107-2116页
For patients with acute myeloid leukemia (AML) who are 75 years of age or older or who are ineligible for intensive induction chemotherapy, azacitidine or decitabine plus venetoclax is the standard of care, but parenteral administration imposes a burden on patients and providers. Oral decitabine-cedazuridine, approved in Europe for AML, has pharmacokinetic properties equivalent to those of intravenous decitabine but provides limited survival benefit as monotherapy.
20. Phase 3 Trial of Secukinumab in Polymyalgia Rheumatica.
作者: John H Stone.;Frank Buttgereit.;Alain Saraux.;Wolfgang A Schmidt.;Christian Dejaco.;Robert Spiera.;Bhaskar Dasgupta.;Edit Drescher.;Andrew Jordan.;Libor Novosad.;Daiki Nakagomi.;Yoshinobu Koyama.;Sergio Duran-Barragan.;Gerald Tracey.;Adeline Ruyssen-Witrand.;Andrea Rubbert Roth.;Juanzhi Fang.;Jennifer Ng.;Renuka Hiremath.;Roselyne Raffner.;Ruvie Martin.;Silvia Napoletano.;Songqiao Huang.;Julian Storim.;Manmath Patekar.; .
来源: N Engl J Med. 2026年395卷7期637-647页
Polymyalgia rheumatica is a common inflammatory disease characterized by pain and stiffness in the shoulders and hips. Glucocorticoids are the first-line treatment, but relapses and glucocorticoid-related toxic effects are common, which underscores the need for effective alternatives. Secukinumab is a fully human monoclonal antibody that selectively inhibits interleukin-17A.
|